Compare Rockwell Automation (ROK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs Twist Bioscience Corp — how do they compare? Rockwell Automation trades at $426.07 (market cap $47.65B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Rockwell Automation is far larger — about 5.7× Twist Bioscience Corp's market cap, and Rockwell Automation pays a 1.29% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| ROK | TWST | |
|---|---|---|
Market Cap | $47.65B | $8.42B |
Sector | Industrials | Health |
52-Week High | $495.08 | $153.10 |
52-Week Low | $333.75 | $24.16 |
Enterprise Value | $50.79B | $8.35B |
Dividend Yield | 1.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $429.13, down 1.08% on the day, with a bearish technical signal and near-term support at $427. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue for 2025 was $8.34B, with a net income margin of 13.38%, though profitability has moderated from 2023 peaks. Recent news highlights expansion in AI-driven quality systems and remote support capabilities.
The stock offers a 19.8% upside to the consensus price target of $514, supported by analyst optimism on margin expansion and reshoring trends. However, high valuation multiples (P/E 40.18) and mixed technical indicators suggest near-term volatility. Key risks include execution on growth initiatives and macroeconomic pressures on industrial spending.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
